Company launches premium fetaf bovine serum product.
SAN DIEGO, Calif., January 30, 2017 -- Nucleus Biologics, a cell culture products supplier, has launched its first premium product: a fetal bovine serum (FBS) that provides customers access to an exclusive source in Australia.
This FBS is exceptionally low-viral risk and is ideal for bioproduction or research applications in stem cells, vaccines, antibodies, CAR-T cells, immunotherapies or any sensitive scientific experiments.
The company saw a need in the market for a higher quality FBS that better met the needs of scientists.
Traditionally, most sellers of FBS source their raw material under multiple short-term supply agreements which may yield product inconsistencies and fluctuations in availability and price. Thus, FBS has turned into a volatile commodity.
The company believed there was a way to create a new standard and redesign the traditional FBS supply chain to allow greater transparency between the source and the scientist.
The process will exceed customer expectations for product consistency, quality and long-term price stability, the company said.
To accomplish this, Nucleus Biologics partnered with Tavistock Group, as well as Australian Agricultural Company (AACo), as its exclusive source. AACo, one of Australia's oldest companies, has the largest herd in Australia and over 16 million acres of land under its control.
The company's supply chain yields an FBS that increases consistency across lots, has Farm-to-Flask traceability back to the animal, and allows for longer-term pricing arrangements.
To demonstrate product consistency, Nucleus Biologics FBS is characterized with 59 tests that include biochemical, hormonal, viral and functional profiles.
With a dedicated source from within Australia, Nucleus Biologics ensures an FMD- and BSE-free product.
The FBS is also manufactured under a controlled and transparent process yielding an extremely low viral load, low hemoglobin and low endotoxin serum.
Nucleus Biologics also processes its FBS in a facility that is FDA registered, ISO 9001:2008 certified and follows cGMP. The processing facility has years of experience and is regularly audited internally and externally by entities including large pharmaceutical companies.
Researchers who don't focus on the quality of FBS could be getting inconsistent results that result in costly experiment delays. Last year, a Colorado researcher and others were stalled for about six months when sequential batches of serum failed an initial screen.
The estimated cost of the failed experiments was more than $45,000 in just personnel and consumables. Unrecognized variations in serum might explain why they could not get consistent results. Researchers who don't test their serum could run into trouble and risk expensive delays.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Cells & Cell Culture|
|Publication:||Stem Cell Business News|
|Date:||Feb 6, 2017|
|Previous Article:||Collaboration targets kidney tissue research.|
|Next Article:||Athersys closes public stock offering.|